Solid Biosciences Inc.

SLDB · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.7%

Institutions107.3%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	–	–	$8.09M	$13.62M	$0	$0	$0
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$179.21M	-$129.73M	-$106.45M	-$72.25M	-$88.41M	-$119.32M	-$75.69M
Operating income as a percentage of revenue.	–	–	-1315.2%	-530.5%	–	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$174.32M	-$124.70M	-$85.98M	-$72.19M	-$88.29M	-$117.22M	-$74.80M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.99	$-3.06	$-10.10	$-0.68	$-1.70	$-2.00	$-2.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.99	$-3.06	$-10.10	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$59.90M	$80.23M	$155.38M	$119.14M	$154.74M	$76.04M	$86.37M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$232.54M	$188.66M	$260.25M	$232.38M	$171.17M	$103.47M	$139.60M
Everything the company owes — debt, unpaid bills, and other obligations.	$52.53M	$51.42M	$48.59M	$24.17M	$39.08M	$23.42M	$14.41M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$180.01M	$137.25M	$211.67M	$208.21M	$132.09M	$80.05M	$125.18M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$156.30M	-$100.00M	-$97.98M	-$77.76M	-$56.60M	-$92.71M	-$70.20M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$1.15M	$654000	$3.02M	$1.28M	$899000	$4.39M	$7.78M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$157.45M	-$100.65M	-$100.99M	-$79.05M	-$57.50M	-$97.10M	-$77.97M

	You	Peer avg
P/E	–	0.1
Revenue Growth	–	+31.1%
ROE	-65.5%	-160.3%

Solid Biosciences Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison